Delivery Order SPE2DB22D2214-SPE2DB25FS5LT

Award Date 6/17/25
Potential Completion Date 6/18/25
Potential Value $2.5K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Olmesartan Medoxomil 40 mg tablets in 90-count packages, with a ceiling value of $5,672.29. It is a firm-fixed-price contract with an ultimate completion date of April 16, 2025. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Olmesartan Medoxomil 40 mg tablets in 90-count packages, with a ceiling value of $3,720.76 and a period of performance through May 8, 2025. The contract is a firm-fixed-price delivery order, with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Olmesartan Medoxomil 40 mg tablets. The contract has a firm fixed price of $1,170.51 and a performance period ending on June 11, 2025. The contract is not set aside and was awarded on June 10, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the delivery of Olmesartan Medoxomil 40 mg tablets. The contract has a ceiling value of $4,090.08 and is a firm fixed price delivery order with a completion date of May 13, 2025. The contract is not set aside and is an open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
This is a $2,742.52 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of Olmesartan Medoxomil 40 mg tablets. The award has a period of performance through May 9, 2025 and was not set aside for any socioeconomic category. AmerisourceBergen holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a comprehensive...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, to provide Olmesartan Medoxomil 40 mg tablets. The contract has a firm fixed price of $1,091.34 and a completion date of May 20, 2025. The award is not designated as a set-aside contract, indicating open competition. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Olmesartan Medoxomil 40 mg tablets. The contract has a ceiling value of $1,188.05 and a performance period through May 9, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Olmesartan Medoxomil 40 mg tablets in 90-count packages, with a ceiling value of $7,189.33 and a period of performance through April 2025. The contract is a firm-fixed-price delivery order and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distribution and healthcare solutions provider. The $1,948.90 firm fixed-price contract is for the delivery of 4565231401 - Olmesartan Medoxomil 40 mg tablets (30s) and has a period of performance through July 24, 2024. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Olmesartan Medoxomil 40 mg tablets in 30-count packages, with a ceiling value of $3,693.39 and a completion date of May 14, 2025. The contract is a firm fixed-price delivery order and is not set aside for any specific business type. Amerisourcebergen Drug Corp holds a significant Indefinite...
  • SPE2DB22D2214
    Indefinite Delivery Contract
  • SPE2DB22D2214-SPE2DB25FS5LT
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Olmesartan Medoxomil 40 mg tablets. The contract has a firm fixed price, has no set-aside designation, and has a ceiling value of $2,492.73. The ultimate completion date for this delivery order is June 18, 2025.

AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which serves as a comprehensive global pharmaceutical support vehicle with a performance period extending through December 2026. This IDC enables the company to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard.

Generated 9/16/25, 10:03 AM